NCT02594267 2021-07-27A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)Acrotech Biopharma Inc.Phase 1 Completed48 enrolled
NCT01789723 2020-01-23Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving FolotynAcrotech Biopharma Inc.Phase 1 Withdrawn
NCT01820091 2020-01-23Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®Acrotech Biopharma Inc.Phase 1 Withdrawn
NCT00554827 2020-01-03Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell LymphomaAcrotech Biopharma Inc.Phase 1 Completed55 enrolled
NCT01134341 2019-12-18Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell LymphomaAcrotech Biopharma Inc.Phase 1 Completed34 enrolled